2. In May 2002, the company invested 30 million yuan, designed in strict accordance with GMP standards, and an advanced new production base was built in Duyiwei Industrial Park, Wang Ba, Kang County, Gansu Province, and passed the acceptance. * * * produced 6 dosage forms, 32 varieties, a number of national new drugs, exclusive varieties and protected varieties of traditional Chinese medicine, with an annual processing capacity of 65438+ 0.500 tons of original research drugs. At the same time, the company successfully moved from Lanzhou to Kangxian Duyiwei Bio-industrial Park.
3. From June 2003 to 10, the company passed the national GMP certification at one time.
4. On June 5438+ 10, 2005, the company successfully industrialized the production of Duyiwei soft capsules and obtained the approval for the production of new drugs.
5. In February 2006, the company successfully passed the GMP certification of the soft capsule production line workshop, which laid the foundation for the mass production of new products.
6. In July 2006, the company successfully industrialized the production of Gongliuning capsules and obtained the approval for the production of new drugs.
7. In 2006, the company successfully planted Lamiophlomis rotata in the national Chinese herbal medicine production support project, and built a Lamiophlomis rotata planting base covering an area of 30,000 mu in Maqu County, Gannan, which is of great significance for protecting the wild resources of Lamiophlomis rotata and promoting its industrial application. At the same time, the company also applied for a certificate of origin in the Ministry of Commerce, further forming an exclusive advantage.
8. On June 5438+February 2006, the third extraordinary shareholders' meeting of the company in 2006 was held in Chengdu. After voting, the overall restructuring plan of the company was adopted. On February 29th, 65438, the company was officially restructured into Gansu Duyiwei Biopharmaceutical Co., Ltd., and the first board of directors and board of supervisors were formed, and 9 directors and 3 supervisors were elected.
9. In June, 2007, the company and the Journal of Continuing Education of Chinese Medical Association jointly held "Medical Research Thinking and Thesis Writing Class" in Chongqing, Dalian, Beijing and Zibo, which greatly improved the company's popularity.
10, in March 2008, the company was listed on the small and medium-sized board market in Shenzhen, becoming the first pharmaceutical listed company in Gansu Province.
1 1 and 20 12 years, the company clearly defined medical service as the strategic direction and fully intervened in the medical service industry.
12 and 20 13, the company made great strides in the field of medical mergers and acquisitions, and successively acquired five hospitals.
13, 20 14, the company changed its name to the strategic direction of strengthening medical care of Hengkang Medical, began to acquire large-scale second-class hospitals, and actively participated in the restructuring of public hospitals.